Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03032042
Other study ID # 17-0101
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date January 2017
Est. completion date February 2018

Study information

Verified date June 2021
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Molecular testing of the gut microbiome and enteric pathogens is rapidly moving beyond targeted PCR testing to next generation sequencing techniques. In addition, the current state of monitoring for soil-transmitted helminth infections is moving increasingly from microscopic techniques to molecular techniques. The targeted PCR test for soil transmitted helminth diagnosis has been validated on stool samples, but not rectal swabs. Bulk stool samples are logistically challenging and time-intensive to collect, thus participation is often far from optimal. Rectal swabs are more efficient and may result in higher participation. In this study, children will be randomized to either albendazole, azithromycin, or both drugs, after which both rectal swabs and bulk stool samples will be collected. The investigators will compare the PCR test for soil transmitted helminth infections using both the rectal swabs and the bulk stool samples. In addition, the investigators will analyze the gut microbiome of the children using next generation sequencing techniques to gain insight into effects of mass drug administration.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 2018
Est. primary completion date February 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 5 Years
Eligibility Inclusion Criteria: - all children 0 to 5 (up to 6th birthday) Exclusion Criteria: - individuals with a macrolide allergy - refusal of parent/guardian

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azithromycin

Albendazole

Delayed treatment
Albendazole+Azithromycin

Locations

Country Name City State
Ethiopia The Carter Center Ethiopia Addis Ababa

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Microbial diversity in the intestinal microbiomes of children aged 1-60 months Microbiota diversity in the intestinal microbiomes of children aged 1-60 months in azithromycin-treated, albendazole-treated, azithromycin+albendazole-treated and delayed treatment arms using phylogenetic distance measures Day 7
Secondary Sensitivity of Soil-transmitted helminth infection detection in rectal swab versus bulk stool sample in children 0-5 The investigators use PCR to identify soil transmitted helming infections in rectal swab samples and bulk stool sample from the same child. Using the bulk stool sample as the gold standard, the investigators will calculate the sensitivity, specificity, PPV, and NPV of the rectal swabs for detecting the various helminth infections. Day 7
See also
  Status Clinical Trial Phase
Completed NCT03036059 - Twice Yearly Treatment for the Control of LF Phase 4
Active, not recruiting NCT03598842 - Tuberculosis - Learning the Impact of Nutrition N/A
Active, not recruiting NCT03441893 - Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis Phase 1/Phase 2
Completed NCT04227925 - The Longevity of Trichuris Trichiura Colonization
Recruiting NCT04642755 - Comorbidities and Coinfections in Latent TB